Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 50 and 80 year old.~* Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American College of Rheumatology).~* Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS).~* Radiological Classification: Kellgren-Lawrence scale greater or equal to 2.~* Body mass index between 20 and 35 kg/m2.~* Ability to follow during the study period.~Exclusion Criteria:~* Bilateral Osteoarthritis of the Knee requiring treatment in both knees.~* Previous diagnosis of polyarticular disease.~* Severe mechanical deformation.~* Arthroscopy during the previous 6 months.~* Intraarticular infiltration of hyaluronic acid in the last 6 months.~* Systemic autoimmune rheumatic disease.~* Poorly controlled diabetes mellitus.~* Blood dyscrasias.~* Immunosuppressive or anticoagulant treatments.~* Treatment with corticosteroids in the 3 months prior to inclusion in the study.~* NSAID therapy within 15 days prior to inclusion in the study.~* Patients with a history of allergy to penicillin or streptomycin.~* Allergy to hyaluronic acid or poultry proteins.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Hialuronic acid (Type: ACTIVE_COMPARATOR): Single intraarticular injection of Hyaluronic acid (Hyal One)
- Hyaluronic acid and MSC 10 (Type: ACTIVE_COMPARATOR): Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells
- Hyaluronic acid AND MSC 100 (Type: ACTIVE_COMPARATOR): Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells

Based on this trial design, predict the completion outcome and termination type (if applicable).